{
  "DOI": "10.1007/s10689-021-00269-7",
  "ISSN": [
    "1389-9600",
    "1573-7292"
  ],
  "URL": "http://dx.doi.org/10.1007/s10689-021-00269-7",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eA number of case/family reports have proposed \u003cjats:italic\u003ePTCH2\u003c/jats:italic\u003e as a putative Gorlin Syndrome (GS) gene, but evidence to support this is lacking. We assessed our cohort of 21 \u003cjats:italic\u003ePTCH1/SUFU\u003c/jats:italic\u003e negative GS families for \u003cjats:italic\u003ePTCH2\u003c/jats:italic\u003e variants and assessed current evidence from reported cases/families and population data. In our \u003cjats:italic\u003ePTCH1/SUFU\u003c/jats:italic\u003e variant negative GS cohort (25% of total), no pathogenic or likely pathogenic \u003cjats:italic\u003ePTCH2\u003c/jats:italic\u003e variants were identified. In addition, none of the previously published \u003cjats:italic\u003ePTCH2\u003c/jats:italic\u003e variants in GS families/cases could be considered pathogenic or likely pathogenic using current guidelines. The absence of clear pathogenic variants in GS families and the high frequency of Loss-of-function (LoF) variants in the general population, including the presence of homozygous LoF variants without a clinical phenotype, mean that it is untenable that \u003cjats:italic\u003ePTCH2\u003c/jats:italic\u003e is a GS gene. \u003cjats:italic\u003ePTCH2\u003c/jats:italic\u003e should not be included in panels for genetic diagnosis of GS.\u003c/jats:p\u003e",
  "alternative-id": [
    "269"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "1 April 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 2,
      "value": "16 June 2021"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 3,
      "value": "25 June 2021"
    },
    {
      "group": {
        "label": "Declarations",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "DGE has received travel Grants from AstraZeneca."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "Routine screening was carried out through the diagnostic service at the West Midlands Genetics Laboratory, UK. Research analysis was carried out with ethical approval by the National Research Ethics Service Committee North West 7 (10/H1008/74)."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-3184-0817",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Smith",
      "given": "Miriam J.",
      "sequence": "first"
    },
    {
      "ORCID": "http://orcid.org/0000-0002-8482-5784",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Evans",
      "given": "D. Gareth",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "Familial Cancer"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2021,
        6,
        25
      ]
    ],
    "date-time": "2021-06-25T05:02:30Z",
    "timestamp": 1624597350000
  },
  "deposited": {
    "date-parts": [
      [
        2022,
        6,
        16
      ]
    ],
    "date-time": "2022-06-16T07:18:44Z",
    "timestamp": 1655363924000
  },
  "funder": [
    {
      "DOI": "10.13039/100014653",
      "award": [
        "IS-BRC-1215-20007"
      ],
      "doi-asserted-by": "publisher",
      "name": "Manchester Biomedical Research Centre"
    }
  ],
  "indexed": {
    "date-parts": [
      [
        2024,
        2,
        1
      ]
    ],
    "date-time": "2024-02-01T16:29:52Z",
    "timestamp": 1706804992052
  },
  "is-referenced-by-count": 8,
  "issn-type": [
    {
      "type": "print",
      "value": "1389-9600"
    },
    {
      "type": "electronic",
      "value": "1573-7292"
    }
  ],
  "issue": "3",
  "issued": {
    "date-parts": [
      [
        2021,
        6,
        25
      ]
    ]
  },
  "journal-issue": {
    "issue": "3",
    "published-print": {
      "date-parts": [
        [
          2022,
          7
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            6,
            25
          ]
        ],
        "date-time": "2021-06-25T00:00:00Z",
        "timestamp": 1624579200000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2021,
            6,
            25
          ]
        ],
        "date-time": "2021-06-25T00:00:00Z",
        "timestamp": 1624579200000
      }
    }
  ],
  "link": [
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-021-00269-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/article/10.1007/s10689-021-00269-7/fulltext.html",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "https://link.springer.com/content/pdf/10.1007/s10689-021-00269-7.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "343-346",
  "prefix": "10.1007",
  "published": {
    "date-parts": [
      [
        2021,
        6,
        25
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2021,
        6,
        25
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2022,
        7
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "author": "DG Evans",
      "key": "269_CR1",
      "unstructured": "Evans DG, Farndon PA (1993) Nevoid basal cell carcinoma syndrome. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT et al (eds) GeneReviews(R). University of Washington, Seattle",
      "volume-title": "GeneReviews(R)",
      "year": "1993"
    },
    {
      "DOI": "10.1200/JCO.2014.58.2569",
      "author": "MJ Smith",
      "doi-asserted-by": "publisher",
      "first-page": "4155",
      "journal-title": "J Clin Oncol",
      "key": "269_CR2",
      "unstructured": "Smith MJ, Beetz C, Williams SG, Bhaskar SS, O’Sullivan J, Anderson B, Daly SB, Urquhart JE, Bholah Z, Oudit D, Cheesman E, Kelsey A, McCabe MG, Newman WG, Evans DG (2014) Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 32:4155–4161",
      "volume": "32",
      "year": "2014"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104669",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "530",
      "journal-title": "J Med Genet",
      "key": "269_CR3",
      "unstructured": "Evans DG, Oudit D, Smith MJ, Rutkowski D, Allan E, Newman WG, Lear JT (2017) First evidence of genotype-phenotype correlations in gorlin syndrome. J Med Genet 54:530–536",
      "volume": "54",
      "year": "2017"
    },
    {
      "DOI": "10.1093/hmg/8.2.291",
      "author": "I Smyth",
      "doi-asserted-by": "publisher",
      "first-page": "291",
      "journal-title": "Hum Mol Genet",
      "key": "269_CR4",
      "unstructured": "Smyth I, Narang MA, Evans T, Heimann C, Nakamura Y, Chenevix-Trench G, Pietsch T, Wicking C, Wainwright BJ (1999) Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Hum Mol Genet 8:291–297",
      "volume": "8",
      "year": "1999"
    },
    {
      "DOI": "10.1136/jmg.2007.055343",
      "author": "Z Fan",
      "doi-asserted-by": "publisher",
      "first-page": "303",
      "journal-title": "J Med Genet",
      "key": "269_CR5",
      "unstructured": "Fan Z, Li J, Du J, Zhang H, Shen Y, Wang CY, Wang S (2008) A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. J Med Genet 45:303–308",
      "volume": "45",
      "year": "2008"
    },
    {
      "author": "LL Xu",
      "first-page": "15",
      "journal-title": "Beijing Da Xue Xue Bao Yi Xue Ban",
      "key": "269_CR6",
      "unstructured": "Xu LL, Li TJ (2008) PTCH2 gene alterations in keratocystic odontogenic tumors associated with nevoid basal cell carcinoma syndrome. Beijing Da Xue Xue Bao Yi Xue Ban 40:15–18",
      "volume": "40",
      "year": "2008"
    },
    {
      "DOI": "10.1016/j.ejmg.2020.103842",
      "author": "K Casano",
      "doi-asserted-by": "publisher",
      "first-page": "103842",
      "journal-title": "Eur J Med Genet",
      "key": "269_CR7",
      "unstructured": "Casano K, Meddaugh H, Zambrano RM, Marble M, Torres JI, Lacassie Y (2020) Gorlin-like phenotype in a patient with a PTCH2 variant of uncertain significance. Eur J Med Genet 63:103842",
      "volume": "63",
      "year": "2020"
    },
    {
      "DOI": "10.1007/s10689-013-9623-1",
      "author": "K Fujii",
      "doi-asserted-by": "publisher",
      "first-page": "611",
      "journal-title": "Fam Cancer",
      "key": "269_CR8",
      "unstructured": "Fujii K, Ohashi H, Suzuki M, Hatsuse H, Shiohama T, Uchikawa H, Miyashita T (2013) Frameshift mutation in the PTCH2 gene can cause nevoid basal cell carcinoma syndrome. Fam Cancer 12:611–614",
      "volume": "12",
      "year": "2013"
    },
    {
      "DOI": "10.1038/s41439-019-0041-2",
      "author": "M Altaraihi",
      "doi-asserted-by": "publisher",
      "first-page": "10",
      "journal-title": "Hum Genome Var",
      "key": "269_CR9",
      "unstructured": "Altaraihi M, Wadt K, Ek J, Gerdes AM, Ostergaard E (2019) A healthy individual with a homozygous PTCH2 frameshift variant: are variants of PTCH2 associated with nevoid basal cell carcinoma syndrome? Hum Genome Var 6:10",
      "volume": "6",
      "year": "2019"
    },
    {
      "DOI": "10.3390/ijms21207559",
      "author": "S Onodera",
      "doi-asserted-by": "publisher",
      "first-page": "7559",
      "journal-title": "Int J Mol Sci",
      "key": "269_CR10",
      "unstructured": "Onodera S, Nakamura Y, Azuma T (2020) Gorlin syndrome: recent advances in genetic testing and molecular and cellular biological research. Int J Mol Sci 21:7559",
      "volume": "21",
      "year": "2020"
    },
    {
      "DOI": "10.1038/gim.2015.30",
      "author": "S Richards",
      "doi-asserted-by": "publisher",
      "first-page": "405",
      "journal-title": "Genet Med",
      "key": "269_CR11",
      "unstructured": "Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, Committee ALQA (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology. Genet Med 17:405–424",
      "volume": "17",
      "year": "2015"
    },
    {
      "DOI": "10.3343/lmo.2020.10.2.175",
      "author": "WK Kwon",
      "doi-asserted-by": "publisher",
      "first-page": "175",
      "journal-title": "Lab Med Online",
      "key": "269_CR12",
      "unstructured": "Kwon WK, Kim HT, Yoon YC, Woo HI, Kim J-W (2020) The first Korean case of Gorlin-Goltz syndrome caused by a PTCH2 pathogenic variant identified via whole exome sequencing. Lab Med Online 10:175–178",
      "volume": "10",
      "year": "2020"
    }
  ],
  "reference-count": 12,
  "references-count": 12,
  "resource": {
    "primary": {
      "URL": "https://link.springer.com/10.1007/s10689-021-00269-7"
    }
  },
  "score": 0,
  "short-container-title": [
    "Familial Cancer"
  ],
  "source": "Crossref",
  "title": [
    "PTCH2 is not a strong candidate gene for gorlin syndrome predisposition"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "21"
}